Supreme Court of Canada: Shoppers Drug Mart can challenge private-label generic Rx ban in Ontario
TORONTO — Canadian pharmacy retailer Shoppers Drug Mart announced on Thursday that the Supreme Court of Canada has granted its application for leave to appeal to Ontario’s ban on private-label generic drugs.
“The company respects the decision of the Supreme Court of Canada and is pleased with the outcome,” the retailer stated. A hearing date has not yet been set, and no further details were provided.
According to Reuters, Canada’s Katz Group also has been granted leave to challenge the ban.
The Supreme Court of Canada granted Shoppers’ application for leave to appeal the December 2011 decision of the Court of Appeal of Ontario that restored the prohibition on private-label generic drug products in the province of Ontario.
The ban has hampered pharmacies’ earnings and has kept Shpppers from selling its private-label drugs in the province. Reuters reported that Katz Group, which operates Rexall drug stores, wants to launch a similar business.
National Council on Aging launches flu shot drive with CDC targeting seniors
WASHINGTON — The National Council on Aging last week introduced a new national Flu + You campaign to improve vaccination rates among seniors.
“Each year in the U.S., about 9-out-of-10 flu-related deaths and more than 6-out-of-10 flu-related hospitalizations occur in adults 65 and older,” stated Richard Birkel, acting SVP healthy aging and director of NCOA’s Self-Management Alliance. “For this reason NCOA wants … to ensure that people in this age group and those who care for them fully understand the importance of annual immunization and the vaccine options available to them."
As part of the Flu + You initiative, Carolyn Bridges, associate director for adult immunizations at the Centers for Disease Control and Prevention, and Birkel will be participating in interviews with media across the nation.
The Flu + You campaign also will be conducting regional programming in Arizona, Florida and Pennsylvania — all states with large populations of older adults — to reach local residents with information about the dangers of influenza and vaccine options for adults 65 years and older.
NCOA’s Flu + You campaign is made possible through a collaboration with Sanofi Pasteur.
NextGen, Nipro Diagnostics create telemedicine capability monitoring diabetes patients
HORSHAM, Pa. — NextGen Healthcare Information Systems on Wednesday announced a telemedicine agreement with Nipro Diagnostics that would enable users of the company’s NextGen Ambulatory EHR instant access to data points captured by patients at home who are using the Nipro TrueResult blood-glucose monitoring system.
“Home monitoring will become even more important as healthcare providers move toward patient-centered medical home and accountable care organization models,” stated Scott Decker, president of NextGen Healthcare. “Seamlessly integrating data directly from a patient’s meter into NextGen Healthcare’s Ambulatory EHR provides physicians with the necessary tools to better manage the health of their patients with chronic disease while also affording them the ability to reduce hospitalizations and improve quality of life. This allows patients to stay at home healthier and longer before requiring interventions.”
The Nipro Diagnostic Blood Glucose interface imports blood-glucose readings from the TrueResult device into NextGen Healthcare’s Ambulatory EHR, allowing users to view and graph the information captured. The NextGen Nipro Glucose Meter Interface enables electronic downloading of glucose measurements from a Nipro Diagnostics blood-glucose meter into the EHR, automatically populating the appropriate templates and fields, where data can be viewed and analyzed by a physician.
Physicians will gain an immediate benefit from seamlessly performing diagnostic tests with direct entry of information into a patient’s chart, the company stated, eliminating the need to manually re-enter patient data while streamlining processes, reducing data entry errors and increasing efficiencies.